Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Takami Ishizuka
Observed name:
Ishizuka, Takami
Institution:
National Center of Neurology and Psychiatry
Observed institutions:
National Center of Neurology and Psychiatry,
National Center Hospital of Neurology and Psychiatry,
Translational Medical Center, National Center of Neurology and Psychiatry
ORCID:
0000-0003-3641-3328
Observed ORCID:
0000-0003-3641-3328
OpenAlex ID:
A5069994012
Phase 1/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy
2025
·
Hirofumi Komaki
, Eri Takeshita
, et al.
·
Cell Reports Medicine
·
29
PDF
First-in-human clinical trial of the NKT cell-stimulatory glycolipid OCH in multiple sclerosis
2023
·
Wakiro Sato
, Daisuke Noto
, et al.
·
Therapeutic Advances in Neurological Disorders
·
15
Systemic administration of the antisense oligonucleotide NS ‐089/ NCNP ‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/ II clinical trial
2023
·
Takami Ishizuka
, Hirofumi Komaki
, et al.
·
Neuropsychopharmacology Reports
·
11
PDF
Efficacy and Safety of the Natural Killer T Cell–Stimulatory Glycolipid OCH-NCNP1 for Patients With Relapsing Multiple Sclerosis: Protocol for a Randomized Placebo-Controlled Clinical Trial
2023
·
Tomoko Okamoto
, Takami Ishizuka
, et al.
·
JMIR Research Protocols
·
1
PDF
2.08P Noncontrolled, nonblinded, multicenter, collaborative phase 2 trial of steroid therapy for Fukuyama congenital muscular dystrophy
2026
·
Takatoshi Sato
, Terumi Murakami
, et al.
·
Neuromuscular Disorders
Sustained freedom from disease activity in secondary progressive multiple sclerosis by targeting invariant NKT cells: a phase 2 trial of OCH
2026
·
Ben JE Raveney
, Tomoko Okamoto
, et al.
·
medRxiv
PDF
Development of a cost-effectiveness analysis model for Duchenne muscular dystrophy utilizing the national registry in Japan
2025
·
Takuro Okada
, Hirofumi Komaki
, et al.
·
Scientific Reports
PDF
Nonrandomized Allocation of Steroid Therapy in Patients With Fukuyama Congenital Muscular Dystrophy: Study Protocol for a Phase II Clinical Trial
2025
·
Terumi Murakami
, Takatoshi Sato
, et al.
·
Neuropsychopharmacology Reports
PDF
Protocol for using MYOD1-transduced human urine-derived cells as a predictive platform for exon skipping therapy in Duchenne muscular dystrophy
2025
·
Katsuhiko Kunitake
, Takami Ishizuka
, et al.
·
STAR Protocols
Phase II Clinical Trial of NKT Cell-targeting Glycolipid OCH-NCNP1 for Patients with Relapsing Multiple Sclerosis (P9-6.015)
2024
·
Tomoko Okamoto
, Wakiro Sato
, et al.
·
Neurology
Show more works
View as search
Works count:
12
Citation count:
56
H-index:
3
I10-index:
3
Year
Topic
Type